Dic(17;18)(p11.2;p11.2) is a recurring abnormality in chronic lymphocytic leukaemia associated with aggressive disease

Interphase cytogenetics are commonly used to identify clonal abnormalities in chronic lymphocytic leukemia (CLL) patients but fail to identify recurrent translocations that ultimately can direct more focused molecular characterization. Given the importance of del(17p13.1) in CLL outcome, we performed an extensive review of 1213 patients undergoing metaphase cytogenetics at our institution and identified 16 (1·3%) with a recurrent unbalanced translocation between the p arms of chromosomes 17 and 18 that results in a dicentric chromosome with loss of much of 17p and 18p. The dic(17;18)(p11.2;p11.2) was associated with a complex (three or more unrelated cytogenetic abnormalities) karyotype in 12 patients (75%) at the time that the abnormality was first identified, and eventually associated with a complex karyotype in 94% of patients. IGHV mutational analysis was un‐mutated in 88% of cases where evaluation was possible. Except for one patient who was diagnosed with CLL incidentally during a workup for metastatic tonsillar cancer, all patients identified with dic(17;18)(p11.2;p11.2) met criteria for disease treatment, with a median time from diagnosis to first treatment of 15 months. Our data demonstrate that dic(17;18)(p11.2;p11.2) is a novel recurrent cytogenetic abnormality in CLL associated with early age at diagnosis and accelerated disease progression. Future efforts to identify genes disrupted by this translocation are warranted and ongoing.

[1]  J. Byrd,et al.  Chronic lymphocytic leukemia. , 2010, Hematology. American Society of Hematology. Education Program.

[2]  A. Hagemeijer,et al.  Chromosomal translocations independently predict treatment failure, treatment-free survival and overall survival in B-cell chronic lymphocytic leukemia patients treated with cladribine , 2007, Leukemia.

[3]  John C Reed,et al.  Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  Sainan Wei,et al.  Loss of 17p is a major consequence of whole-arm chromosome translocations in hematologic malignancies. , 2007, Cancer genetics and cytogenetics.

[5]  K. Stamatopoulos,et al.  Clinical, immunophenotypic, and molecular profiling of trisomy 12 in chronic lymphocytic leukemia and comparison with other karyotypic subgroups defined by cytogenetic analysis. , 2006, Cancer genetics and cytogenetics.

[6]  Tait D. Shanafelt,et al.  Loss of TP53 is due to rearrangements involving chromosome region 17p10∼p12 in chronic lymphocytic leukemia , 2006 .

[7]  M. Caligiuri,et al.  Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  F. Ajchenbaum‐Cymbalista,et al.  Binet's staging system and VH genes are independent but complementary prognostic indicators in chronic lymphocytic leukemia. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  S. Knuutila,et al.  More extensive genetic alterations in unmutated than in hypermutated cases of chronic lymphocytic leukemia , 2003, Genes, chromosomes & cancer.

[10]  L. Shaffer,et al.  Genome architecture catalyzes nonrecurrent chromosomal rearrangements. , 2003, American journal of human genetics.

[11]  D. Neme,et al.  Cytogenetic, FISH, and molecular studies in a case of B‐cell chronic lymphocytic leukemia with karyotypic evolution , 2002, European journal of haematology.

[12]  Axel Benner,et al.  Stromal-derived factor 1 inhibits the cycling of very primitive human hematopoietic cells in vitro and in NOD/SCID mice. , 2002, Blood.

[13]  D. Oscier,et al.  Multivariate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors. , 2002, Blood.

[14]  A Benner,et al.  Genomic aberrations and survival in chronic lymphocytic leukemia. , 2000, The New England journal of medicine.

[15]  F. Solé,et al.  Dicentric (17;18) in a case of atypical B-cell chronic lymphocytic leukemia. , 2000, Cancer genetics and cytogenetics.

[16]  J. Benichou,et al.  Expression of unmutated VH genes is a detrimental prognostic factor in chronic lymphocytic leukemia. , 2000, Blood.

[17]  T J Hamblin,et al.  Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. , 1999, Blood.

[18]  N. Chiorazzi,et al.  Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. , 1999, Blood.

[19]  G. Salles,et al.  Translocations involving the short arm of chromosome 17 in chronic B-lymphoid disorders: frequent occurrence of dicentric rearrangements and possible association with adverse outcome , 1999, Leukemia.

[20]  F. Mancini,et al.  p53 expression in B-cell chronic lymphocytic leukemia: a marker of disease progression and poor prognosis. , 1998, Blood.

[21]  A Benner,et al.  p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. , 1995, Blood.

[22]  B. Quesnel,et al.  p53 Mutations Are Associated With Resistance to Chemotherapy and Short Survival in Hematologic Malignancies , 1994 .

[23]  C. Preudhomme,et al.  Mutations of the p53 gene in B-cell chronic lymphocytic leukemia: a report on 39 cases with cytogenetic analysis. , 1992, Leukemia.

[24]  S. Knuutila,et al.  Prognostic subgroups in B-cell chronic lymphocytic leukemia defined by specific chromosomal abnormalities. , 1990, The New England journal of medicine.

[25]  Mark J. Thomas,et al.  A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis , 1981, Cancer.

[26]  L. Shaffer,et al.  ISCN 2009 - An International System for Human Cytogenetic Nomenclature , 2009 .

[27]  Daniel L Van Dyke,et al.  Loss of TP53 is due to rearrangements involving chromosome region 17p10 approximately p12 in chronic lymphocytic leukemia. , 2006, Cancer genetics and cytogenetics.

[28]  B. Quesnel,et al.  p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. , 1994, Blood.

[29]  P. Nowell,et al.  Cytogenetic Findings and Survival in B-cell Chronic Lymphocytic Leukemia. Second IWCCLL Compilation of Data on 662 Patients. , 1991, Leukemia & lymphoma.

[30]  Iscn International System for Human Cytogenetic Nomenclature , 1978 .

[31]  D C Case,et al.  Clinical staging of chronic lymphocytic leukemia. , 1977, The Journal of the Maine Medical Association.